DBVT News and Press, DBV Technologies S.A. From 01/08/20

DBV Technologies (NASDAQ: DBVT ) announces positive long-term results from the open-label extension study (( PEOPLE )) of its Phase 3 clinical trial, PEPITES , evaluating Viaskin Peanut in peanut-allergic children aged 4 - 11 years. More news on: DBV Technologies S.A., Healthcare stocks...

Montrouge, France, January 8, 2020 DBV Technologies Reports Positive Three-Year, Long-Term Data from the PEOPLE Phase III Open-Label Extension Study of Viaskin Peanut in Children with Peanut Allergy Patients demonstrated durable, long-term clinical benefit with an additional...

Montrouge, France, January 2, 2020 DBV Technologies Announces Appointment of Ramzi Benamar as Chief Financial Officer DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Ramzi Be...

Editor's note: Seeking Alpha is proud to welcome Eugene Capital Advisors as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA PREMIUM. Click here to find out more » About DB...

Monthly information regarding the total number of voting rights and  total number of shares of the Company (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 * Total net =...

Montrouge, France, November 5, 2019 DBV Technologies to Present at the Stifel 2019 Healthcare Conference DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Kevin Trapp, Chief Commercial Off...

Montrouge, France, October 24, 2019 DBV Technologies to Highlight the Burden of Peanut Allergy and Patient Experiences with Viaskin Peanut at ACAAI 2019 New analysis evaluates quality of life in patients receiving investigational Viaskin Peanut DBV Technologies (Euronext: DBV - ISIN:...

Montrouge, France, October 10, 2019 DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs) DBV Technologies (the “Company ...

DBV Technologies (NASDAQ: DBVT ) has priced its global offering of (i) 7,914,622 ordinary shares (15,829,244 ADSs) in U.S., Canada and countries outside Europe at $6.59/ADS (ii) a private placement of 1,569,444 ordinary shares in Europe (including France) at €12.04/ordinary share. ...

DBV Technologies Announces Pricing of $125 million ( € 114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: D...